Likewise, a meta-analysis of the five cardiovascular outcome trials with DPP-4 inhibitors available at the end of 2018 showed a neutral effect on the risk for stroke, similar to the profile of safety, but showed a lack of benefits in terms of the risk for myocardial infarction, cardiovascular death, or heart failure [46]. The gene discussed is DPP4; the disease is stroke disorder.